Navigation Links
AcelRx Pharmaceuticals Reports First Quarter 2011 Financial Results
Date:5/12/2011

ess of manufacturing components for the ARX-01 device.  We have selected the CRO to conduct the Phase 3 studies for ARX-01, and anticipate initiating enrollment in our first Phase 3 study, an efficacy study in major abdominal surgery, in the second half of 2011.  We anticipate initiating enrollment for our second Phase 3 study, a head-to-head comparison of ARX-01 to the standard of care, IV PCA morphine, in early 2012."

"We continue to believe that ARX-01 could become the treatment of choice for patient-controlled management of moderate-to-severe post-operative pain," said Mr. King.

Financial OutlookAcelRx anticipates that research and development expenses will increase over the next several years as it seeks to complete Phase 3 development of ARX-01.  AcelRx does not intend to initiate the third ARX-01 Phase 3 study, an efficacy study in orthopedic hip and knee replacement surgeries until additional funding is obtained.  The development of ARX-02,a product candidate for the treatment of cancer breakthrough pain, and ARX-03, a product candidate for mild sedation and pain relief in procedures conducted in a physician's office, will not advance until additional funding or the identification of a partner to support this effort is secured. Additionally, AcelRx anticipates increases in general and administrative expenses due to costs associated with operating as a public company and expansion of its corporate infrastructure to support ongoing development of its product candidates.

AcelRx believes its current cash and cash equivalents, and the interest earned thereon, are sufficient to fund operations through the second quarter of 2012.

About AcelRx Pharmaceuticals, Inc. Based in Redwood City, CA, AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX) is a specialty pharmaceutical company focused on the development and commercialization of innovati
'/>"/>

SOURCE AcelRx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. AcelRx European Patent Covering its NanoTab® Sublingual Delivery Technology for Acute and Breakthrough Pain Pipeline Products Emerges From Opposition Period
2. AcelRx Pharmaceuticals to Present at the JMP Securities Research Conference
3. AcelRx Pharmaceuticals Reports Fourth Quarter and Full-Year 2010 Financial Results
4. AcelRx Pharmaceuticals to Present at the Cowen and Company 31st Annual Health Care Conference
5. AcelRx Pharmaceuticals Announces Pricing of Its Initial Public Offering
6. AcelRx Pharmaceuticals Files Registration Statement for Proposed Initial Public Offering
7. AcelRx Announces Positive Phase 2 Results From a Study of ARX-02 Sufentanil NanoTab(TM) Breakthrough Pain Management System in Treating Cancer Breakthrough Pain
8. AcelRx to Present at the Lazard 6th Annual Healthcare Conference
9. AcelRx Programs to be Featured in Oral Presentations at the American Society of Anesthesiologists 2009 Annual Meeting
10. AcelRx Announces Positive Phase 2 Results from a Study of ARX-01 Sufentanil NanoTabs in Treating Post-Operative Pain
11. AcelRx Initiates a Phase 2 Study to Evaluate Functionality of Its ARX-01 Sufentanil NanoTab PCA System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... -- Demers Ambulances is proud to announce it has signed ... the states of Mississippi , ... "This will enable Demers to effectively meet the ... Vice-President for Demers Ambulances. "Emergency Equipment Professionals has three service ... Alabama , giving them a strategic advantage. Local ...
(Date:9/2/2015)... Sept. 2, 2015  Boca Raton Regional Hospital,s ... begun performing ultra-minimally invasive left atrial appendage ligation ... such as Coumadin, Xarelto or Effient. Dr. Cartledge, ... Hospital, is one of a select group of ... two microscopic incisions in order to seal off ...
(Date:9/2/2015)... 2, 2015  Aethlon Medical, Inc. (Nasdaq: AEMD ), ... will be presenting at the Rodman & Renshaw 17th Annual ... at 9:35 a.m. ET on Thursday, September 10, 2015. ... public via live audio webcast which can be accessed by ... at http://www.aethlonmedical.com . The webcast will be archived for ...
Breaking Medicine Technology:Demers Ambulances has named Emergency Equipment Professionals (EEP) Inc. as their dealer for the states of MS, AL and TN 2Boca Regional Introduces Ultra-Minimally Invasive Surgical Procedure for Atrial Fibrillation Patients 2Boca Regional Introduces Ultra-Minimally Invasive Surgical Procedure for Atrial Fibrillation Patients 3
... a developer of Healthcare Technology Networks ("HTN") designed to ... today announces the launch of its proprietary Opioid Management ... United States Bone & Joint Decade , ... suffering from musculoskeletal disease filled 1.6 billion prescriptions. While ...
... SPRING, Md., April 6, 2012 Sunpeaks Ventures, ... "Sunpeaks Ventures") and its wholly owned subsidiary Healthcare Distribution ... has entered into a sponsorship agreement ("Agreement") with a ... Clotamin, including advertising, media, and promotional elements. The Agreement ...
Cached Medicine Technology:Med-Tek Launches the First Evidenced Based Opioid Management Program (OMP) 2Sunpeaks Ventures Inks Sponsorship and Marketing Agreement with Major Sports Team, Clotamin To Be Sold at Walgreens Locations Throughout Oregon and Southern Washington 2Sunpeaks Ventures Inks Sponsorship and Marketing Agreement with Major Sports Team, Clotamin To Be Sold at Walgreens Locations Throughout Oregon and Southern Washington 3
(Date:9/2/2015)... ... ... A recent survey by Consumer Reports ( http://bit.ly/1h67tL8 ) sheds light on ... consumers. It was reported that 33% are paying an average of $39 more out-of-pocket ... $100 compared to last year. Among the drugs that saw the highest increases were ...
(Date:9/2/2015)... MN (PRWEB) , ... September 02, 2015 , ... ... commercializing products for the upper extremity surgical market, announced today that more than ... for trigger releases in the hand. Plus, nearly 70 of these procedures ...
(Date:9/2/2015)... ... September 02, 2015 , ... Ovarian cancer continues to be the deadliest of ... ovarian cancer in her lifetime is approximately 1 in 75. This year it is ... 14,000 will die. , There is no test to detect ovarian cancer. A ...
(Date:9/2/2015)... ... ... “ G-Hold ” was featured on NewsWatch as part of its monthly ... Forstrom, a technology expert and special reporter for NewsWatch, conducted the review and shared ... while reducing the likelihood of it dropping. , Tablets like the iPad and Samsung ...
(Date:9/2/2015)... ... September 02, 2015 , ... Please join the world renowned ... which was established by the Foundation in 2007 with the help of Massachusetts ... more research remains our top priority,” commented Christine Buckley, Executive Director of the ...
Breaking Medicine News(10 mins):Health News:Watertree Health President Responds to Consumer Reports Survey on Rising Prescription Drug Prices 2Health News:Trigger Tome Surpasses 600 Successful Patient Procedures 2Health News:National Ovarian Cancer Coalition's DFW Chapter Features First Annual Teal Lights Display This Friday, September 4th, "National Wear Teal Day" 2Health News:National Ovarian Cancer Coalition's DFW Chapter Features First Annual Teal Lights Display This Friday, September 4th, "National Wear Teal Day" 3Health News:Comfortably Hold a Tablet with G-Hold Hands Free Tablet Holder 2Health News:September Celebrated as Brain Aneurysm Awareness Month 2
... ,Renovis, Inc. (Nasdaq: RNVS ), a biopharmaceutical ... for major medical needs in the areas of,neurological ... under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, ... Trade Commission,requesting additional information with regard to the ...
... a lifetime, researchers say, , , THURSDAY, April 3 (HealthDay News) ... victims of maltreatment in 2006 during their first year of ... their first week of life, federal officials reported Thursday. ... risk for nonfatal maltreatment of children less than 1 year ...
... scientists are the first to observe in living cells a ... of the four building blocks that comprise DNA. Also ... replication. The findings, which will be published in the ... to new cancer treatments that prevent cancer cells from replicating ...
... of health care information to,patients for disease management, ... Today URAC called,for public comment on revisions ... accreditation programs. URAC is seeking input from any,interested ... organizations and health plans. The deadline for public,comment ...
... 2008 ... WHO/ WHAT: "Iron Andy" Holder, an Ironman Arizona competitor who was ... this Sunday,s triathlon to encourage others who have chronic ... condition and to live without limits., ...
... 3, 2008 -- A study led by researchers at Memorial ... a particular type of molecule to promote metastasis -- the ... 90 percent of all cancer-related deaths. The study is published ... work examines how cells in the body communicate with each ...
Cached Medicine News:Health News:Renovis Announces Expiration of Hart-Scott-Rodino (HSR) 30-Day Waiting Period; Merger With Evotec on Track to Close in Early May, 2008 2Health News:Renovis Announces Expiration of Hart-Scott-Rodino (HSR) 30-Day Waiting Period; Merger With Evotec on Track to Close in Early May, 2008 3Health News:Renovis Announces Expiration of Hart-Scott-Rodino (HSR) 30-Day Waiting Period; Merger With Evotec on Track to Close in Early May, 2008 4Health News:More Than 90,000 U.S. Infants Are Victims of Abuse or Neglect 2Health News:More Than 90,000 U.S. Infants Are Victims of Abuse or Neglect 3Health News:Enzyme complex could be key to new cancer treatments 2Health News:URAC Releases Draft Standards for Public Input for Nine Health Care Management Accreditation Programs 2Health News:Ironman Competitor with Diabetes Encourages Others to Live Without Limits; Competes in Ironman Arizona in Tempe 2Health News:Researchers learn how signaling molecule orchestrates breast cancer's spread 2
Alvis foreign body spud 4 3/4 inches, oval curette 1 x 3 mm with fine point....
... is made from MMA/VP material and has a ... is supplied with the base curve and total ... is available in a power range of -30.00DS ... of protective and therapeutic applications including the controlled ...
... soft contact lenses can be used as ... to relieve corneal pain in the treaent ... as bullous keratopathy, corneal erosions, entropion, corneal ... post-surgical conditions resulting from cataract extraction and ...
Cottle-Joseph Double Hook 12 mm wide....
Medicine Products: